Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved. SkinTE® is a first-in-class ...

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of ...

MALMÖ, SE / ACCESS Newswire / June 30, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the fili ...

Deadline to register is July 21. For more details, visit The IC3 Movement’s 10th Annual Conference and Expo 2026 will be on ...

The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid can add it through traditional fixed infrastructure ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...

The opportunity is also attracting billions of dollars in investment. As more people seek treatment and awareness of mental health continues to grow, the global Major Depressive Disorder treatment ...

Global demand for rapid diagnostics continues to accelerate as the U.S. market is forecast to reach USD 7.10 Billion by 2035 and Europe USD 6.36 Billion, supported by expanding home testing, clinical ...

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...